{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:13:30Z","timestamp":1793747610750,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Nanjing Municipal Health Commission's key development project in medicine","award":["ZKX23020"],"award-info":[{"award-number":["ZKX23020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02316-y","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:17:09Z","timestamp":1776755829000},"page":"927-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis"],"prefix":"10.1007","volume":"86","author":[{"given":"Qiaoling","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6947-1869","authenticated-orcid":false,"given":"Dayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"3","key":"2316_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106718","volume":"61","author":"J Salmanton-Garc\u00eda","year":"2023","unstructured":"Salmanton-Garc\u00eda J, Au WY, Hoenigl M, et al. The current state of laboratory mycology in Asia\/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents. 2023;61(3):106718. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106718.","journal-title":"Int J Antimicrob Agents"},{"key":"2316_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017. https:\/\/doi.org\/10.3390\/jof3040057.","journal-title":"J Fungi"},{"issue":"4","key":"2316_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.medcli.2024.01.045","volume":"163","author":"M Machado","year":"2024","unstructured":"Machado M, Fort\u00fan J, Mu\u00f1oz P. Invasive aspergillosis: a comprehensive review. Med Clin (Barc). 2024;163(4):189\u201398. https:\/\/doi.org\/10.1016\/j.medcli.2024.01.045.","journal-title":"Med Clin (Barc)"},{"key":"2316_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00140-18","author":"JP Latg\u00e9","year":"2019","unstructured":"Latg\u00e9 JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev. 2019. https:\/\/doi.org\/10.1128\/cmr.00140-18.","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"2316_CR5","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/s1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24(7):e428\u201338. https:\/\/doi.org\/10.1016\/s1473-3099(23)00692-8.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2316_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360. https:\/\/doi.org\/10.1093\/cid\/ciw326.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2316_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"2316_CR8","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.23109","volume":"110","author":"D Caillot","year":"2007","unstructured":"Caillot D, Thi\u00e9baut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740\u20136. https:\/\/doi.org\/10.1002\/cncr.23109.","journal-title":"Cancer"},{"issue":"2","key":"2316_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/m13-2508","volume":"162","author":"KA Marr","year":"2015","unstructured":"Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81\u20139. https:\/\/doi.org\/10.7326\/m13-2508.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2316_CR10","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","volume":"34","author":"R Herbrecht","year":"2018","unstructured":"Herbrecht R, Kuessner D, Pooley N, et al. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr Med Res Opin. 2018;34(12):2187\u201395. https:\/\/doi.org\/10.1080\/03007995.2018.1502659.","journal-title":"Curr Med Res Opin"},{"key":"2316_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1504826","volume":"15","author":"J Cheng","year":"2024","unstructured":"Cheng J, Han H, Kang W, et al. Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis. Front Microbiol. 2024;15:1504826. https:\/\/doi.org\/10.3389\/fmicb.2024.1504826.","journal-title":"Front Microbiol"},{"key":"2316_CR12","doi-asserted-by":"publisher","first-page":"1530999","DOI":"10.3389\/fphar.2024.1530999","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhao J, Wang Y, et al. The efficacy and safety of first-line monotherapies in primary therapy of invasive aspergillosis: a systematic review. Front Pharmacol. 2024;15:1530999. https:\/\/doi.org\/10.3389\/fphar.2024.1530999.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2316_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09477-9","volume":"24","author":"A Liu","year":"2024","unstructured":"Liu A, Xiong L, Wang L, et al. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis. BMC Infect Dis. 2024;24(1):581. https:\/\/doi.org\/10.1186\/s12879-024-09477-9.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"2316_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.29271\/jcpsp.2025.09.1173","volume":"35","author":"L Zhu","year":"2025","unstructured":"Zhu L, Yang X, Li K, et al. Efficacy and safety of antifungal medicines in the treatment of invasive aspergillosis: a network meta-analysis. J Coll Physicians Surg Pak. 2025;35(9):1173\u20139. https:\/\/doi.org\/10.29271\/jcpsp.2025.09.1173.","journal-title":"J Coll Physicians Surg Pak"},{"key":"2316_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1500529","volume":"15","author":"YS Alsowaida","year":"2024","unstructured":"Alsowaida YS, Alshoumr B, Alowais SA, et al. Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis. Front Pharmacol. 2024;15:1500529. https:\/\/doi.org\/10.3389\/fphar.2024.1500529.","journal-title":"Front Pharmacol"},{"key":"2316_CR16","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim SJ, Lee J, et al. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013. https:\/\/doi.org\/10.4178\/epih.e2019013.","journal-title":"Epidemiol Health"},{"issue":"11","key":"2316_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/m14-2385.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2316_CR18","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"key":"2316_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2316_CR20","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 16 Apr 2024."},{"issue":"47","key":"2316_CR21","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","volume":"35","author":"BR da Costa","year":"2014","unstructured":"da Costa BR, Juni P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J. 2014;35(47):3336\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehu424.","journal-title":"Eur Heart J"},{"issue":"2","key":"2316_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163\u201371. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2316_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16(1):e1080. https:\/\/doi.org\/10.1002\/cl2.1080.","journal-title":"Campbell Syst Rev"},{"issue":"4","key":"2316_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","journal-title":"PLoS Med"},{"issue":"3","key":"2316_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41(3):818\u201327. https:\/\/doi.org\/10.1093\/ije\/dys041.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2316_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/myc.13013","volume":"63","author":"MP Cheng","year":"2020","unstructured":"Cheng MP, Orejas JL, Arbona-Haddad E, et al. Use of triazoles for the treatment of invasive aspergillosis: a three-year cohort analysis. Mycoses. 2020;63(1):58\u201364. https:\/\/doi.org\/10.1111\/myc.13013.","journal-title":"Mycoses"},{"issue":"6","key":"2316_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315. https:\/\/doi.org\/10.1056\/NEJMoa020191.","journal-title":"N Engl J Med"},{"issue":"4","key":"2316_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1086\/341401","volume":"35","author":"R Bowden","year":"2002","unstructured":"Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(4):359\u201366. https:\/\/doi.org\/10.1086\/341401.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2316_CR29","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high\u2013loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289\u201397. https:\/\/doi.org\/10.1086\/514341.","journal-title":"Clin Infect Dis"},{"issue":"10273","key":"2316_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509. https:\/\/doi.org\/10.1016\/s0140-6736(21)00219-1.","journal-title":"Lancet"},{"issue":"10020","key":"2316_CR31","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/s0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(15)01159-9.","journal-title":"Lancet"},{"issue":"4","key":"2316_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","volume":"79","author":"TF Patterson","year":"2000","unstructured":"Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore). 2000;79(4):250\u201360. https:\/\/doi.org\/10.1097\/00005792-200007000-00006. (I3 Aspergillus Study Group).","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2316_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","volume":"81","author":"N Singh","year":"2006","unstructured":"Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320\u20136. https:\/\/doi.org\/10.1097\/01.tp.0000202421.94822.f7.","journal-title":"Transplantation"},{"issue":"6","key":"2316_CR34","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cncr.23311","volume":"112","author":"RY Hachem","year":"2008","unstructured":"Hachem RY, Boktour MR, Hanna HA, et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112(6):1282\u20137. https:\/\/doi.org\/10.1002\/cncr.23311.","journal-title":"Cancer"},{"issue":"3","key":"2316_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","volume":"45","author":"II Raad","year":"2015","unstructured":"Raad II, Zakhem AE, Helou GE, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45(3):283\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.08.012.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2316_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31762","volume":"14","author":"E Mahmoud","year":"2022","unstructured":"Mahmoud E, Alzahrani M, Loutfi S, et al. Comparing invasive pulmonary aspergillosis mortality between liposomal amphotericin B and voriconazole in patients with hematological malignancy or hematopoietic stem cell transplantation. Cureus. 2022;14(11):e31762. https:\/\/doi.org\/10.7759\/cureus.31762.","journal-title":"Cureus"},{"issue":"11","key":"2316_CR37","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.21057","volume":"103","author":"DP Kontoyiannis","year":"2005","unstructured":"Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer. 2005;103(11):2334\u20137. https:\/\/doi.org\/10.1002\/cncr.21057.","journal-title":"Cancer"},{"issue":"1","key":"2316_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1086\/375219","volume":"37","author":"PK Linden","year":"2003","unstructured":"Linden PK, Coley K, Fontes P, et al. Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B. Clin Infect Dis. 2003;37(1):17\u201325. https:\/\/doi.org\/10.1086\/375219.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2316_CR39","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1086\/515033","volume":"27","author":"M Ellis","year":"1998","unstructured":"Ellis M, Spence D, Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27(6):1406\u201312. https:\/\/doi.org\/10.1086\/515033.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2316_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","volume":"103","author":"AC Leenders","year":"1998","unstructured":"Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103(1):205\u201312. https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00944.x.","journal-title":"Br J Haematol"},{"key":"2316_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1324","author":"WJ Heinz","year":"2016","unstructured":"Heinz WJ, Cornely OA, Selleslag D, et al. Hepatic safety of isavuconazole compared with voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation complicated by invasive mold disease: a post-hoc analysis from the SECURE study. Open Forum Infect Dis. 2016. https:\/\/doi.org\/10.1093\/ofid\/ofw172.1324.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2316_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/17460913.2024.2423530","volume":"20","author":"Q Liu","year":"2025","unstructured":"Liu Q, Chen P, Xiao D, et al. Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China. Future Microbiol. 2025;20(3):213\u201325. https:\/\/doi.org\/10.1080\/17460913.2024.2423530.","journal-title":"Future Microbiol"},{"issue":"1","key":"2316_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/13696998.2025.2483098","volume":"28","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Inoue S, Onishi Y. Cost-utility analysis of isavuconazole compared with the standard of care as a first-line therapy for patients with invasive fungal infection prior to differential pathogen diagnosis in Japan. J Med Econ. 2025;28(1):460\u201370. https:\/\/doi.org\/10.1080\/13696998.2025.2483098.","journal-title":"J Med Econ"},{"issue":"suppl_1","key":"2316_CR44","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1093\/ofid\/ofu052.534","volume":"1","author":"N Khandelwal","year":"2014","unstructured":"Khandelwal N, Franks B, Shi F, et al. 826Health economic outcome analysis of patients randomized in the SECURE phase III trial comparing isavuconazole to voriconazole for primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi. Open Forum Infect Dis. 2014;1(suppl_1):S236\u20137. https:\/\/doi.org\/10.1093\/ofid\/ofu052.534.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"2316_CR45","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/jphp.12802","volume":"69","author":"FS Tonin","year":"2017","unstructured":"Tonin FS, Steimbach LM, Borba HH, et al. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. J Pharm Pharmacol. 2017;69(12):1672\u201383. https:\/\/doi.org\/10.1111\/jphp.12802.","journal-title":"J Pharm Pharmacol"},{"issue":"11","key":"2316_CR46","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1086\/423381","volume":"39","author":"J Maertens","year":"2004","unstructured":"Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563\u201371. https:\/\/doi.org\/10.1086\/423381.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2316_CR47","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/jac\/dkw276","volume":"71","author":"M Siopi","year":"2016","unstructured":"Siopi M, Siafakas N, Vourli S, et al. Dose optimization of voriconazole\/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic\/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis. J Antimicrob Chemother. 2016;71(11):3135\u201347. https:\/\/doi.org\/10.1093\/jac\/dkw276.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2316_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/17476348.2017.1325322","volume":"11","author":"MW McCarthy","year":"2017","unstructured":"McCarthy MW, Petraitis V, Walsh TJ. Combination therapy for the treatment of pulmonary mold infections. Expert Rev Respir Med. 2017;11(6):481\u20139. https:\/\/doi.org\/10.1080\/17476348.2017.1325322.","journal-title":"Expert Rev Respir Med"},{"key":"2316_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/jof11010070","author":"A Zubovskaia","year":"2025","unstructured":"Zubovskaia A, Vazquez JA. Invasive aspergillosis in the intensive care unit. J Fungi. 2025. https:\/\/doi.org\/10.3390\/jof11010070.","journal-title":"J Fungi"},{"issue":"10","key":"2316_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.7326\/m15-2521","volume":"164","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Attiche N, Bafeta A, et al. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med. 2016;164(10):666\u201373. https:\/\/doi.org\/10.7326\/m15-2521.","journal-title":"Ann Intern Med"},{"key":"2316_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-018-3055-3","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Wang Y, Zhang T, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18:1\u201313.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"2316_CR52","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1093\/jac\/dkw045","volume":"71","author":"H Jin","year":"2016","unstructured":"Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2316_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107619","volume":"66","author":"Z Tan","year":"2025","unstructured":"Tan Z, Zhang N, Liang B, et al. Therapeutic drug monitoring of isavuconazole: trends and update. Int J Antimicrob Agents. 2025;66(6):107619. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107619.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2316_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00074-23","volume":"37","author":"M Hoenigl","year":"2024","unstructured":"Hoenigl M, Arastehfar A, Arendrup MC, et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clin Microbiol Rev. 2024;37(2):e0007423. https:\/\/doi.org\/10.1128\/cmr.00074-23.","journal-title":"Clin Microbiol Rev"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02316-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02316-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:39:56Z","timestamp":1778855996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02316-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02316-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      and declare: funding from the Nanjing Municipal Health Commission\u2019s key development project in medicine; no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data generated or analyzed during this study are included in this article and its additional information files.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"QG and YC contributed equally to this work. HZ and DC conceived the study and secured funding. QG, YC, PD, and DC designed the search strategy. QG, YC, PD, and DC performed literature searches and screened articles for inclusion. QG, YC, and PD extracted data, conducted analyses, and assessed the quality of eligible studies. QG and YC performed meta-analyses under the supervision of JH and DC. QG and YC drafted the study protocol and manuscript. JH, HZ, and DC contributed to manuscript development through critical review and editing. DC is the guarantor of the study. The corresponding author attests that all listed authors meet authorship criteria and confirms no omissions of eligible contributors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}